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ProliferationMicroRNA-490-3p (miR-490-3p) has been implicated in several human malignancies; however, its
potential functions and the underlying molecular mechanisms in osteosarcoma progression remain
largely unclear. Here, we showed that miR-490-3p was down-regulated in osteosarcoma cell lines.
Ectopic expression of miR-490-3p decreased cell proliferation, induced G1 arrest and apoptosis
in vitro and inhibited tumorigenicity in a mouse xenograft model. Furthermore, miR-490-3p bound
directly to HMGA2 mRNA 30UTR and mediated a decrease in HMGA2 mRNA and protein expression.
Re-expression of HMGA2 reversed the inhibitory effects of miR-490-3p. Further investigations
showed an inverse correlation between low miR-490-3p and high HMGA2 expression in osteosar-
coma tissues. Taken together, our results suggest that miR-490-3p functions as a potential tumor
suppressor by down-regulating HMGA2 expression directly, and it may represent a potential
therapeutic target for patients with osteosarcoma.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Osteosarcoma is the most common primary bone malignancy
and is derived from primitive bone-forming mesenchymal cells;
it occurs most frequently in adolescents and young adults [1].
Although the development of adjuvant and neo-adjuvant
chemotherapy has improved the survival rate of patients with
osteosarcoma from 15% to 60–70% [2,3], overall clinical outcomes
remain unsatisfactory, especially for patients with metastasis or
recurrent osteosarcoma. In recent years, evidence has accumulated
of the molecular alterations involved in osteosarcoma progression.
However, the highly complex molecular mechanism of osteosar-
coma has not been elucidated fully. Furthermore, it is important
to search for novel markers for osteosarcoma to optimize thera-
peutic strategies and predict clinical outcomes.
Over the past decade, a class of endogenous non-coding small
RNAs of 22 nucleotides, known as microRNAs (miRNAs), have
emerged as potential regulators of various critical biologicalprocesses, such as the proliferation, differentiation, progression
and apoptosis of tumor cells [4,5]. miRNAs function as post-
transcriptional regulators, pairing with the 30 untranslated region
(30UTR) of target mRNAs either by cleaving mRNA molecules or
by inhibiting translation [6,7]. Therefore, dysregulation of
oncogenic miRNAs (targeting tumor suppressor genes) or
tumor-suppressive miRNAs (targeting oncogenes) may lead to dys-
function of cancer cells, inducing proliferation and apoptosis [8].
Alteration in miR-490-3p has been reported in several types of
cancer. Reports have shown that miR-490-3p functions as a tumor
suppressor in A549 lung cancer cells, gastric cancer and ovarian
carcinoma by targeting CCND1, SMARCD1 and CDK1 [9–11]. miR-
490-3p plays an oncogenic role in hepatocellular carcinoma cells
by targeting endoplasmic reticulum–Golgi intermediate compart-
ment protein 3 (ERGIC3) [12]. Thus, whether miR-490-3p acts as
a tumor suppressor or an oncogene may depend on the cellular
context. Previously, Nakatani et al. revealed that measurement of
miR-490-3p achieved sufficient statistical power to predict prog-
nosis in Ewing’s sarcoma [13]. However, the function of miR-
490-3p in osteosarcoma pathogenesis, as well as the molecular
mechanisms by which miR-490-3p exerts its functions and modu-
lates the malignant phenotypes of osteosarcoma cells, has not been
fully understood.
In this study, we tested the hypothesis that miR-490-3p may
also function as a tumor suppressor in osteosarcoma. As expected,
miR-490-3p was significantly down-regulated in osteosarcoma
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ation in vitro and tumorigenicity in vivo. We further demonstrated
that miR-490-3p induced G1/S cell cycle arrest and apoptosis in
osteosarcoma cells. Interestingly, we screened and identified a
novel miR-490-3p target within high mobility group a isoform 2
(HMGA2). Over-expression of HMGA2 may reverse the suppressive
function of miR-490-3p in osteosarcoma cells. In addition, a nega-
tive correlation between the expression of miR-490-3p and
HMGA2 was found in osteosarcoma specimens. Taken together,
our results indicate that miR-490-3p, acting as a tumor suppressor
and potential therapeutic target against osteosarcoma, may repress
tumor proliferation by direct inhibition of HMGA2 expression.
2. Materials and methods
2.1. Cell lines and cell culture
Osteosarcoma cell lines (HOS, Saos2, U2OS, MG63), the immor-
talized normal osteoblastic cell line hFOB 1.19, and HEK293T were
obtained from the Institute of Biochemistry and Cell Biology at the
Chinese Academy of Sciences (Shanghai, China). Osteosarcoma cell
lines were grown in RPMI1640 supplemented with 10% heat-
inactivated FBS, 2 mM L-glutamine, 100 U/ml penicillin and
100 mg/ml streptomycin. HEK293T cells were cultured in DMEM
with 10% heat-inactivated FBS, 2 mM L-glutamine, 100 U/ml peni-
cillin and 100 mg/ml streptomycin. All the cell lines were cultured
at 37 C in a humidified incubator with 5% CO2.
2.2. Osteosarcoma tissues
Osteosarcoma and corresponding adjacent non-tumorous tis-
sues were obtained from 22 Chinese patients who underwent sur-
gery between 2011 and 2013 at Changhai Hospital (Shanghai,
China). All surgically resected tissues were immediately preserved
in liquid nitrogen. Detailed clinical pathology information for all
samples was available. The protocol was approved by the Ethics
Committee of the Second Military Medical University, Shanghai,
China. Informed consent was obtained from each patient.
2.3. RNA extraction and quantitative real-time PCR (qRT-PCR)
Total RNA, including miRNA, was extracted from tissues or cells
using the miRNeasy Mini Kit (Qiagen, Valencia, CA, USA) according
to the manufacturer’s instructions. One microgram of total RNA
was reverse transcribed to cDNA using a Prime Script RT reagent
Kit (Takara, Dalian, China). Real-time PCR was performed with
the SYBR green Premix Ex Taq II (Takara, Dalian, China) using an
Applied Biosystems Step One Plus Real-Time PCR System (Applied
Biosystems, Carlsbad, CA, USA). b-Actin and U6 were used as the
endogenous controls for measurement of mRNA expression level
and miRNA expression analysis, respectively. The sequences of
the primers for HMGA2 were 50-CCAACCGGTGAGCCCTCT-30 (for-
ward) and 50-TTGAGCTGCTTTAGAGGGAC-30 (reverse). The
sequences of the primers for b-actin were 50-CTCCATCCTGGCCTC
GCTGT-30 (forward) and 50-GCTGTCACCTTCACCGTTCC-30 (reverse).
2.4. Construction of plasmids
The miR-490-3p agomir and negative control were purchased
from Ribobio (Guangzhou, China). The 30UTR segment of HMGA2
was amplified from normal human cDNA and inserted into the psi-
CHECK2 vector (Promega, Madison, WI, USA), downstream of the
luciferase stop codon. The primers for HMGA2-30UTR were 50-AA
CTCGAGCGATTTCTACCTCAGCAGCA-30 (forward) and 50-ATGCGGC
CGCTTTCGCTCCTCCCACCTCAT-30 (reverse). A mutant form of
HMGA2 30UTR was generated by the Quik Change Site-DirectedMutagenesis Kit (Stratagene, La Jolla, CA, USA). The HMGA2 frag-
ment was amplified from the Homo sapiens full open reading frame
cDNA library and cloned into a pcDNA3.1(+) vector to generate
pcDNA3.1-HMGA2 recombinant plasmids.
2.5. MTT and colony formation assays
Cells (5  103) transfected with miR-490-3p agomir or negative
control were seeded into 96-well plates and stained with 0.5 mg/
ml sterile MTT dye (Sigma–Aldrich, St. Louis, MO, USA) for 4 h at
37 C, following which the culture medium was discarded and an
extra 150 ll dimethyl sulfoxide (Sigma–Aldrich) added. The
absorbance at 490 nm was measured at 24, 48, 72 and 96 h after
transfection. The colony formation assay was performed as
described previously [14]. Briefly, cells were trypsinized and
seeded on six-well plates (400 cells/well). After 2 weeks, the colo-
nies were stained with 1% crystal violet and the number of colonies
was counted.
2.6. Tumor xenografts
All protocols involving animal experiments were undertaken in
accordance with the National Institute of Health Guide for the Care
and Use of Laboratory Animals, with the approval of the Scientific
Investigation Board of Second Military Medical University,
Shanghai, China. The 6-week-old BALB/c-nudemice were randomly
divided into two groups (n = 5 per group) and Saos2 cells over-
expressing miR-490-3p or negative control (2  106) were injected
subcutaneously into the scapula of each mouse. Tumor volume was
determined every week using an external caliper and calculated
using the equation (L W2)/2. The mice were sacrificed 6 weeks
after inoculation and the tumors were excised and weighed.
2.7. Cell cycle and cell apoptosis analysis
Osteosarcoma cells were transfected with the indicated oligos
or plasmids in six-well plates. After transfection for 48 h, the cells
were collected and washed with PBS three times. For cell cycle
analysis, the collected cells were fixed with 70% ethanol overnight
at 20 C, and subsequently treated with RNaseA (Sigma–Aldrich)
for 30 min at 37 C, following which they were stained with 50 lg/
ml propidium iodide (PI) (Sigma–Aldrich) for another 10 min. After
incubation, the cells were subjected to flow cytometry analysis
using a FACSCalibur (BD Biosciences, Bedford, MA, USA). Apoptosis
was detected by Annexin V-FITC (BD Biosciences) and PI (BD
Biosciences) staining according to the manufacturer’s instructions,
followed by flow cytometry analysis.
2.8. Western blotting
The cells were lysed in RIPA buffer (Thermo Scientific, Rockford,
IL, USA) containing complete protease inhibitors. The protein con-
centration was determined using the BCA Protein Assay Kit (Pierce,
Rockford, IL, USA). Western blotting was performed as a standard
protocol. In brief, 40 lg total proteins were separated by 10% SDS–
PAGE and transferred to PVDF membranes (Millipore, Billerica,
MA, USA). The membranes were blocked with 5% non-fat milk and
then incubated with primary antibody overnight at 4 C, followed
by incubation with a horseradish peroxidase-conjugated secondary
antibody. Protein bands were visualized using an enhanced chemi-
luminescence kit (Millipore). GAPDH was normalized as a loading
control. The antibodies used in this study were as follows. Rabbit
monoclonal antibodies against p21 (#2947), cleaved Caspase 9(c-
Casp, #7237), cleaved PARP (c-PARP, #9541), HMGA2 (#8179) and
GAPDH were obtained from Cell Signaling Technology (Danvers,
MA, USA). Rabbit anti-cyclin D1 (sc-753) was obtained from Santa
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2.9. Luciferase assay
The HEK293T cells (5  103 per well) were seeded in 96-well
plates on the day before transfection. The cells were
co-transfected with 120 ng miR-490-3p agomir or negative control
and 30 ng luciferase reporter vectors containing the psiCHECK-2-
HMGA2-30UTR-WT or psiCHECK-2-HMGA2-30UTR-MUT. Forty-
eight hours after transfection, firefly and Renilla luciferase activities
were measured using the Dual-Luciferase Reporter Assay system
(Promega) according to themanufacturer’s protocol [15]. The firefly
luciferase activities were used as an internal control.
2.10. Statistical analysis
The SPSS 19.0 software was used for the statistical analyses. All
the data are presented as the mean ± standard deviation (S.D.) from
at least three separate experiments. A two-tailed Student t-test was
employed to analyze the differences between two groups. A P value
less than 0.05 was considered statistically significant.Fig. 1. miR-490-3p is down-regulated in osteosarcoma cell lines and modulates cell pr
levels were detected by qRT-PCR in four osteosarcoma cell lines and the human normal os
cells were transiently transfected with miR-490-3p agomir or negative control. The lev
evaluated by the MTT assay at the indicated days. (D) Representative results for colony
were injected into nude mice. Representative images of tumors formed, growth curves
**P < 0.01.3. Results
3.1. miR-490-3p is down-regulated in osteosarcoma cell lines and
modulates cell proliferation in vitro and tumorigenicity in vivo
The level of expression of endogenous miR-490-3p was
detected first by qRT-PCR in four osteosarcoma cell lines (HOS,
Saos2, MG63 and U2OS) and one immortalized normal osteoblastic
cell line (hFOB 1.19). As shown in Fig. 1A, the miR-490-3p levels
were significantly decreased in all four osteosarcoma cell lines
tested, when compared with hFOB 1.19.
In order to test the effect of miR-490-3p on osteosarcoma cell
proliferation, synthetic miR-490-3p agomir and negative control
were transfected into Saos2 and MG63 cells, respectively
(Fig. 1B). Cell viability was measured using MTT assays in vitro,
and we observed that the miR-490-3p group had less viability over
time, when compared with the NC group (Fig. 1C). Consistently, the
upregulated expression of miR-490-3p also visibly attenuated
colony formation (Fig. 1D). Next, a BALB/c nude mouse xenograft
model was applied to evaluate the effect of miR-490-3p on
tumorigenicity. Compared with the control group, miR-490-3p
transfected cells effectively suppressed tumor growth in nudeoliferation in vitro and tumorigenicity in vivo. (A) Relative miR-490-3p expression
teoblastic cell line hFOB 1.19. U6 was used as a loading control. (B) Saos2 and MG63
els of expression of miR-490-3p were measured by qRT-PCR. (C) Cell viability was
formation by the indicated cells. (E) Saos2 cells over-expressing miR-490-3p or NC
for tumor formation and mean tumor weights are shown. Significant differences:
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tumor volume and decreased tumor weight (Fig. 1E).
3.2. miR-490-3p suppresses cell cycle progression and induces
apoptosis of osteosarcoma cells
Tumorigenesis often involves the dysregulation of various bio-
logical processes such as proliferation and apoptosis, and this led
us to investigate the effect of miR-490-3p on cell cycle progression
and apoptosis. To evaluate the effect of miR-490-3p on cell cycle
regulation, both Saos2 and MG63 cells transfected with miR-490-
3p agomir or negative control were subjected to flow cytometry.
Cell cycle analysis showed a distinct decrease in the S-phase cell
population and an increase in the G0/G1-phase cell population in
miR-490-3p agomir transfectants compared with negative control
(Fig. 2A). On Western blots, we found that ectopic miR-490-3p
expression decreased the level of cyclin D1, a regulator of cell cycle
progression, and increased the level of the cell cycle inhibitor p21
(Fig. 2B). To elucidate the role of miR-490-3p in cell apoptosis, we
performed flow cytometric analysis using Annexin V staining, and
Western blotting, to detect the apoptotic rate and protein levels of
pro-apoptotic cleaved Caspase 9 and cleaved PARP, the markers of
cell apoptosis. The apoptotic rate was significantly increased in
miR-490-3p agomir transfected cells compared with NC trans-
fected cells (Fig. 2C). The c-Casp9 and c-PARP were observed to
be highly expressed in miR-490-3p agomir transfected cells but
reduced levels were found in NC cells (Fig. 2D).
3.3. HMGA2 is a direct target gene of miR-490-3p
Toexplore themolecularmechanismresponsible for the function
of miR-490-3p in osteosarcoma, we used three publicly available
databases (TargetScan, picTar and miRanda) to search for poten-
tial direct target genes of miR-490-3p. HMGA2, a high-mobility
group protein with oncogenic function in a variety of tumors [16],
was selected for further analysis. The putative binding site ofFig. 2. miR-490-3p suppresses cell cycle progression and induces apoptosis of osteosarc
490-3p agomir or negative control. (B) Protein expression of cyclin D1 and p21 was measu
assay using flow cytometry. (D) Effects of miR-490-3p on protein expression of apoptosmiR-490-3p and HMGA2 is illustrated in Fig. 3A. The wild-type
(WT) ormutant (MUT) 30UTR ofHMGA2,with amutated seed region
to abolish miR-490-3p binding, was cloned into the psiCHECK-2
plasmid. The dual-luciferase reporter system was employed to
determine whether HMGA2 is a direct target of miR-490-3p. Analy-
sis of the luciferase assay showed that miR-490-3p overexpression
significantly inhibited luciferase activity, when compared with the
negative control, in the wild-type 30UTR of the HMGA2 construct
but not in the mutated construct (Fig. 3B). Moreover, levels of
HMGA2 mRNA and protein expression were significantly lower in
miR-490-3p agomir transfected Saos2 and MG63 cells when
compared with negative control (Fig. 3C and D). These results
suggest that HMGA2 is a direct target of miR-490-3p.3.4. miR-490-3p inhibits osteosarcoma progression by down-
regulating HMGA2
To test the hypothesis that miR-490-3p inhibits osteosarcoma
progression by down-regulating HMGA2, we performed gain
of function assays. Western blotting analysis showed that
pcDNA3.1-HMGA2 transfection effectively replenished miR-490-
3p agomir-induced HMGA2 loss (Fig. 4A). Ectopic expression of
HMGA2 reduced the inhibitory effects of miR-490-3p on cell
viability (Fig. 4B) and cell cycle progression (Fig. 4C), and promoted
the function of cell apoptosis (Fig. 4D). This suggests that the
suppressive effect of miR-490-3p on osteosarcoma progression
may be effectively reversed by HMGA2 overexpression.
These results demonstrate that HMGA2 is a functional target of
miR-490-3p in osteosarcoma cells.
3.5. Negative correlation between decreased miR-490-3p expression
and increased HMGA2 expression in osteosarcoma
It has been demonstrated that miR-490-3p and its target
HMGA2 appear to play a significant role in osteosarcomaoma cells. (A) Flow cytometric analysis of osteosarcoma cells transfected with miR-
red by Western blotting. GAPDH was used as a normalization control. (C) Apoptosis
is-related genes, detected by Western blotting. Significant differences: **P < 0.01.
Fig. 3. HMGA2 is a direct downstream target gene of miR-490-3p. (A) A schematic graph of the construction of wild-type or mutant psiCHECK2-HMGA2 30UTR vectors is
shown. (B) Assays of luciferase activity of HEKT293 cells transfected with luciferase vectors containing wild-type or mutant HMGA2 30UTR and agomiR-490-3p or negative
control, respectively. The expression of HMGA2 was analyzed by qRT-PCR (C) and Western blotting (D). Significant differences: **P < 0.01.
Fig. 4. miR-490-3p inhibits osteosarcoma progression mainly by down-regulating
HMGA2. (A) Western blotting showed HMGA2 protein expression in Saos2 cells
transfected with negative control, miR-490-3p and miR-490-3p + HMGA2 plasmid,
respectively. HMGA2 significantly suppressed the miR-490-3p-induced reduction
of cell viability (B) and cell cycle progression (C), and promotion of cell apoptosis
(D). Significant differences: **P < 0.01 vs. NC group; &&P < 0.01 vs. miR-490-3p group.
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expression of miR-490-3p and HMGA2 by qRT-PCR in tumor tis-
sues and their matched non-tumor tissues from 22 patients with
osteosarcoma. As shown in Fig. 5A, the expression miR-490-3p
was significantly decreased in tumor tissues when compared with
their matched normal tissues. However, HMGA2 mRNA expressionwas greatly increased in tumor tissues in comparison with normal
tissues (Fig. 5B). Statistical analysis demonstrated that miR-490-3p
expression was inversely correlated with HMGA2 expression
(2-tailed Spearman’s correlation, r = 0.620, P = 0.005, Fig. 5C),
supporting the notion that miR-490-3p downregulation promotes
proliferation in osteosarcoma by directly suppressing HMGA2.
4. Discussion
Aberrant miRNA expression is involved in the initiation and
progression of human cancers [8]. In the present study, we
explored the biological function of miR-490-3p in the pathogenesis
and development of osteosarcoma. The studies provide serial
evidence to demonstrate that miR-490-3p can function as a tumor
suppressor gene in osteosarcoma by targeting the oncogene
HMGA2.
Expression profiles of miRNAs in tumors are highly distinctive.
In Ewing’s sarcoma, Nakatani et al. investigated the miRNA expres-
sion in 49 primary tumors by using the Agilent human miRNA
microarray v.2 and/or qRT-PCR; the results showed that expression
of miR-490-3p achieved sufficient statistical power to predict
prognosis [13]. Previous results have also shown that alteration
in miR-490-3p expression is highly correlated with cell growth
and metastasis in several tumors, such as lung cancer, gastric
cancer, ovarian carcinoma and hepatocellular carcinoma [9–12].
In this study, we found that miR-490-3p is significantly down-
regulated in osteosarcoma cell lines and clinical samples. We sub-
sequently confirmed that overexpression of miR-490-3p inhibited
cell proliferation and cell cycle progression, increased cell apopto-
sis in vitro and suppressed tumorigenicity in vivo.
HMGA2 codes for a chromatin-associated protein that can mod-
ulate transcription by binding to DNA and altering the chromatin
architecture [17,18]. HMGA2 is primarily expressed in undifferen-
tiated cells during fetal development and in various tumors of
mesenchymal origin, including fibroadenomas of the breast, lipo-
mas and uterine leiomyomas [19–21]. HMGA2 is a critical molecu-
lar target of chromosomal aberrations. On one hand, HMGA2
Fig. 5. Negative correlation between decreased miR-490-3p expression and increased HMGA2 expression in osteosarcoma. The expression of miR-490-3p (A) and HMGA2 (B)
was validated with qRT-PCR in 22 pairs of osteosarcoma tissues and their adjacent normal tissues. Significant differences: **P < 0.01. (C) A statistically significant inverse
correlation was shown between miR-490-3p and HMGA2 mRNA levels in osteosarcoma specimens (Spearman’s correlation analysis, r = 0.620, P = 0.005).
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partner gene expression, truncation, or generation of fusion genes
encoding chimeric transcripts; on the other hand, the partner gene
may contribute to HMGA2 oncogenic activity, which results in the
truncation of HMGA2 or loss of its 30UTR [22]. Several sources of
evidence highlight the role of the 30UTR region in the negative
regulation of HMGA2 expression by miRNAs [16,23,24]. Multiple
target sites for miRNA let-7, miRNA-98, miR-26a and miR-145 have
been reported in the 30UTR of the HMGA2 gene [25–28], suggesting
a role for these miRNAs in the negative regulation of HMGA2.
The crucial role of HMGA2 in tumorigenesis and malignant
transformation encouraged us to explore the possible function of
HMGA2 in osteosarcoma carcinogenesis. In our study, HMGA2
was upregulated in osteosarcoma tissues. We further demon-
strated using the luciferase reporter assay that miR-490-3p
directly targeted the 30UTR of HMGA2. The mutated miR-490-3p
recognition element of HMGA2 30UTR was able to reverse the
effects of miR-490-3p on osteosarcoma. Additionally, there was a
negative correlation between the expression of miR-490-3p and
HMGA2 in osteosarcoma tissues. These results confirm that
miR-490-3p functions as a tumor suppressive miRNA in osteosar-
coma cells by targeting HMGA2.
Taken as a whole, our results revealed a reciprocal relation
between the miR-490-3p growth suppressor and the HMGA2
oncogene. As a novel tumor suppressor, miR-490-3p was down-
regulated in osteosarcoma, inhibited osteosarcoma cell prolifera-
tion and the cell cycle, and promoted cell apoptosis. Furthermore,
HMGA2 is a novel target gene of miR-490-3p. Over-expression of
HMGA2 rescued the role of miR-490-3p in osteosarcoma. There-
fore, miR-490-3p has the potential to be a promising diagnostic
biomarker and therapeutic target in osteosarcoma.
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